Suboptimal treatment of risk factors for atherosclerosis in critical limb ischemia

International Angiology

Volumn 24, Issue 1, 2005, Pages 59-63

  Barani, Jamal ^a   Mattiasson, I ^a   Lindblad, B ^a   Gottsater A ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Ischemia; Limb; Risk factors

Indexed keywords

ACTIVATED PROTEIN C; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN ANTIBODY; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACTIVATED PROTEIN C RESISTANCE; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INFORMED CONSENT; LIFESTYLE; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; RISK FACTOR; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ANTIBODIES, ANTICARDIOLIPIN; ATHEROSCLEROSIS; COMORBIDITY; FEMALE; HUMANS; ISCHEMIA; LEG; MALE; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 33745291436     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Dormandy JA, Rutherford RB, TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). Management of peripheral arterial disease (PAD). J Vasc Surg 2000;31:S1-S296.
2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
3. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270:465-9.
4. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-81.
5. Wolfe JN. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 1986;73:321.
6. The I.C.A.I. Group. Long term mortality and its predictors in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg 1997;14:91-5.
7. Hertzner NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF, Graor RA et al. Coronary artery disease in peripheral vascular patients: a classification of 1 000 angiograms and results of surgical management. Ann Surg 1984;199:223-33.
8. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990;72:153-84.
9. Mukherjee D, Lingam P, Chetcuti S, Grossman PM, Moscucci M, Luciano AE et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions. Circulation 2002;106:1909-12.
10. Bismuth J, Klitfod L, Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 2001;21:143-6.
11. Burstein M, Scholnik HR, Morfin R. Rapid method for the isolation of proteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-95.
12. Ubbink J, Vermaak W, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocystein levels in human serum. J Chromatogr 1991;565:441-6.
13. Fiskerstrand T, Refsum H, Kvalheim G, Ueland P. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993;39:263-71.
14. Norlund L, Grubb A, Fex G, Leksell H, Nilsson J, Schenk H et al. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998;36:175-8.
15. Hillarp A, Zöller B, Dahlbäck B. Activated protein C resistance as a basis for venous thrombosis. Am J Med 1996;101:534-40.
16. Brostoff J, Scadding GK, Male D, Roitt IM. Clinical Immunology. London: Gower Medical Publishing; 1991:6.6-6.7.
17. Verhaeghe R. Epidemiology and prognosis of peripheral arteriopathy. Drugs 1998,56:1-10.
18. Second European Consensus Document on chronic critical leg ischemia. Eur J Vasc Surg 1992;6 Suppl A:1-32.
19. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994;1:333-9.
20. Da Silva A, Widmer LK, Ziegler HW, Nissen C, Schweizer W. The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. Chronic Dis 1979;32:797-803.
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
22. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C-77C.
23. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
24. Buchwald H, Hunter DW, Tuna N, Williams SE, Boen JR, Hansen BJ et al. Myocardial infarction and percent arteriographic stenosis of culprit lesion: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). Atherosclerosis 1998;138:391-401.
25. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
26. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-64.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
28. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor; ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
30. Ingolfsson IO, Sigurdsson G, Sigvaldason H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol: the Reykjavik Study. J Clin Epidemiol 1994;47:1237-43.
31. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331-40.
32. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987;221:253-60.
33. Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 2003;24:838-44.
34. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
35. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
36. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.
37. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
38. Clagett GP, Sobel M, Jackson MR, Lip GYH, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:609S-26S.
39. Boushey CJ, Beresford SA, Omenn GS, Motulsky AGA. quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
40. Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991;13:128-36.
41. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
42. Meroni PL, Moia M, Derksen RH, Tincani A, McIntyre JA, Arnout JM et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 2003;12:504-7.
43. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
44. Robetorye RS, Rodgers GM. Update on selected inherited venous thrombotic disorders. Am J Hematol 2001;68:256-68.
45. Ouriel K, Green RM, DeWeese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg 1996;23:46-51.
46. Reny JL, Alhenc-Gelas M, Fontana P, Bissery A, Julia PL, Fiessinger JN et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. Thromb Haemost 2004;2:1334-40.